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Synergy is one of the governing principles of the natural world, and is one of the reasons for the increasing 
complexity of the evolutionary process. Broadly speaking, it relates to the cooperative effects produced 
by the interaction between various forces, elements, parts or individuals in a given context. Since the 
last century, some clinical studies have described the increased efficiency of a combination of drugs. 
To study the effects of the drug interactions, the most commonly cited model is that of Loewe, and the 
classical graphical representation is the iso-effect curve (isobologram). Plants contain an enormous 
diversity of specialized micromolecules, therefore there is a high likelihood of interactions between 
them. Through recent synergy studies, various synergistic interactions have been demonstrated among 
extracts of different plants, and between components of the same extract.
Uniterms: Natural extracts. Synergy. Phytotherapeutics. 
Sinergia é um dos princípios que rege o mundo natural, apontado como uma das razões para a crescente 
complexidade do processo evolutivo. De uma forma ampla, ela se refere aos efeitos cooperativos produzidos 
pela interação entre diversas forças, elementos, partes ou indivíduos em um dado contexto. Desde o ultimo 
século, alguns estudos clínicos tem descrito a eficiência ampliada da combinação de fármacos. Para 
estudar os efeitos da interação de fármacos, o modelo mais citado é o da aditividade de Loewe, e também 
a representação clássica é o isobolograma, ou curva iso-efeito. As plantas contem uma diversidade enorme 
de micromoléculas especializadas, e consequentemente, alta probabilidade de interações entre elas. Através 
de estudos recentes dos efeitos sinérgicos, varias interações sinérgicas estão sendo demonstradas entre 
extratos de diferentes plantas e também entre componentes de um mesmo extrato. 
Unitermos: Extratos naturais. Sinergia. Fitoterápicos. 
INTRODUCTION
Synergy is one of the governing principles of the 
natural world. It is not only an effect that is ubiquitous in 
nature, but is also considered the reason for the growing 
complexity of the evolutionary process. Broadly speaking, 
synergy is defined as the combined or cumulative effects 
produced by interactions between various forces, parti-
cles, elements, substances, parts or individuals in a given 
context. It is derived from the Greek synergos, working 
together, or literally, cooperating. Synergy is often asso-
ciated with the clichê “the whole is greater than the sum of 
the parts”, an idea which emerged at the time of Aristotle 
(350 AC), and is described in his work Metaphysics. But 
synergy is not always greater than the sum of the parts, in 
some cases, the synergic result is merely different. Another 
mistaken idea is that synergy always produces positive or 
beneficial effects, which is not always the case.
In pharmacology, since the last century, the medical 
clinic has been aware of the benefits of combining drugs. It 
is observed that isolated medical substances with action in 
just one molecular target are, in general, less effective for 
treating a disease than a therapy with combined medical 
substances, which act on various targets simultaneously 
(multi-target), potentializing the therapeutic effect. Over 
the last 10 years, classical medicine has gradually aban-
doned therapies with a single substance (monotherapy), in 
favor of treatments with a combination of drugs (multithe-
rapy), like the now well-established treatments for AIDS, 
cancer, malaria, hypertension and infections. Another shift 
in paradigm that has been taking place recently is multi-
therapy focused on the activation of mechanisms which 
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protect and repair the organism, rather than destroying 
the agents which cause the damage (Csermely, Agoston, 
Pongor, 2005).
Multi-drug therapy (multi-target, multitherapy) is 
more effective and less vulnerable to adaptive resistance 
because the biological systems are less able to compensate 
the action of two or more substances simultaneously. As 
a result, mono-target drugs are incapable of effectively 
combating complex pathological conditions like cancer 
and infectious diseases (Keith, Zimmermann, 2004). 
The strategy used today for the development of 
many drugs is based on the premise that the drug acts in 
a central molecular target of a given mechanism, which 
involves identifying and validating individual targets and 
their chemical modulators (micromolecules) or biological 
modulators (macromolecules, such as antibodies). The de-
velopment of this process can take decades of investment 
and study, with a very low success rate. The understanding 
that acting on a single target is in most cases, insufficient 
to restore the balance in a biological system, has led to 
the search for new drugs that act on multiple targets, to 
maximize (or potentialize) the therapeutic effect. Thus, the 
principle of synergy becomes a major contemporary chal-
lenge in the discovery of new therapeutic agents (Lehar 
et al., 2007). Zimmermann, Lehar and Keith (2007) cite 
current examples of multi-target therapies. However, the 
effects of combinations of substances, whose result was 
different and not predictable based on the effects of the 
isolated substances, was observed and quantified in 1928 
(Loewe, 1928). Since then, the concepts of synergy, anta-
gonism and additivism have been extensively explored in 
pharmacology and toxicology. 
In the majority of cases, the synergic combinations 
are established based on clinical experience, where the 
drugs already have previously known action for a certain 
pathology. Considering, therefore, that a mixture can have 
synergic effect in a certain target, even without presenting 
initial activity in isolation, the mathematical combination 
of a previous library can greatly increase the therapeutic 
arsenal of previously-described drugs. For example, a 
collection of 1000 substances (drugs or OTC or GRAS) 
gives access to around 500,000 pairs of combinations. 
Furthermore, the variations in the molar proportion and 
liberation sequence of the drugs are also important, and 
spatially increase the scope of the research. In a study 
on synergy in fungicides, 30 drugs were investigated, 
combined in pairs, of which nine are correctly used as 
fungicides and 21 are used for other indications. The 435 
possible combinations of the 30 drugs would produce 22 
synergic combinations, of which none were like known 
fungicide agents, six had combinations between fungicide 
and non-fungicide, and 16 had combinations between two 
non-fungicide drugs (Borisy et al., 2003). 
In the search for synergic drug combinations, mathe-
matical analyses and refined statistics have been developed 
and revised by various researchers (Barrera et al., 2005; 
Berenbaum, 1989; Greco, Bravo, Parsons, 1995). Some 
methods provide only a qualitative conclusion (Loewe 
activity and the classic isobologram), while others also 
provide a quantitative measure of the intensity of the 
interaction, such as the response surface method. These 
differences are due to the mathematical and statistical ri-
gor applied to each one, some methods can be carried out 
manually (isobologram) while others require a computer 
(response surface method). In the same way, some use 
parametric models and others emphasize non-parametric 
models. 
The most widely used and cited model is that of 
Loewe additivity, which is the most commonly used to de-
termine the interaction with various types of experiments, 
and the most common graphic representation is through 
the isobologram (iso-effect curve). 
An isobologram is constructed by outlining on the x 
and y axes the inhibitory doses of two agents, for a given 
effect. If the effect is additive, the totaled doses are pro-
portional to the effect, which is verified by a shift towards 
the straight line on the graph, which connects two doses 
with equal effects, a linear isobol, when the agents are not 
synergic. When the curve of the isobol moves towards 
the origin (concave line) this indicates that the agents in 
the mixture are synergic, and when the opposite occurs 
(convex line) they present antagonism. In other words, the 
same biological effects of the agents in isolation is obtai-
ned at lower (or higher) doses of the mixture (Figure 1).
SYNERGY AND PHYTOTHERAPEUTICS 
It is known that plants contain a wide diversity of 
specialized micromolecules (secondary metabolites), and 
this diversity presupposes a high likelihood of interactions.
The therapeutic indications of medicinal plant-based 
extracts are, in most cases, empirical, and practitioners of 
phytotherapy intuitively believe that a total extract acts 
better than an equivalent dose of an isolated substance 
(Nelson, Kursar, 1999). Through synergy studies, it is 
now possible to prove the validity of this sentence, with 
some recent works confirming the presence of interactions 
and amplified effect in different plant extracts, and also 
between components of the same extract, as exemplified 
in Table I.
Like western phytotherapy, oriental systems like 
Traditional Chinese Medicine and Indian Medicine – 
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Ayurveda - consider synergy an intrinsic part of their 
philosophy. Combined plants and medicinal extracts are 
common, and are found throughout history. They are de-
veloped by empirical observation and formulated for each 
individual, according to their particular characteristics. 
In phytotherapy, there are potentially significant advan-
tages associated with the interaction within and between 
extracts: (1) increased efficiency, (2) reduction of undesi-
rable effects, (3) increase in stability or bioavailability of 
the free agents, and (4) obtaining an adequate therapeutic 
effect with relatively small doses, when compared with a 
synthetic medication (Inui et al., 2007).
The substances that constitute a total extract may be 
academically divided into: active substances, co-effectors 
and matrix formers, and the interaction between them can 
protect the active substances from decomposition. This 
may be one of the reasons why Ayurveda medicine, one 
of the most ancient systems of medicine, incorporates into 
many of its specific formulas a combination of black pepper 
(Piper longum) and ginger (Zinziber officinalis). Black 
pepper contains the alkaloid piperine (1), which increases 
the bioavailability of various drugs (Williamson, 2001).
Determining the pharmacological mechanism of 
action of a plant extract is not an easy task, due mainly to 
the high degree of interactions and the diversity of their 
thousands of components. Often a predominant mecha-
nism may be potentialized by lesser mechanisms. This 
fact, besides producing a more favorable response than 
just one isolated constituent, enables different therapeutic 
responses to the same substances to be determined, depen-
ding on the other substances in the matrix. For example, 
the flavonoid isoorientin (2) is an active component in 
extracts of different plants, such as in Gentiana olivieri, 
which is traditionally used as a hypoglycemiant (Sezik et 
al., 2005), and is also described as an active component 
of Passiflora incarnata, which is a plant with reputed 
sedative and calming properties (Soulimani et al., 1997).
Based on this premise, the sense of seeking to isolate 
an active principle to discover the mode of action of a cer-
tain extract is questionable. Systemic thought suggests that 
it would be more significant to track and evaluate carefully 
prepared plant extracts, to search for their mode of action. 
In fact, what is normally seen when a biomonitored phyto-
chemical fractioning is carried out, is the loss of biological 
activity as the extract is being fractionated, which often 
leads the researcher to believe that the extract is devoid of 
biological activity (Ulrich-Merzenich et al., 2007).
Some studies have also verified the existence of a 
toxic or undesirable effect when a majority component of 
the extract is tested in isolation. For example, coumarin 
(1,2-benzopyrone) is described as the main component 
in the extract guaco (Mikania glomerata, M. laevigata), 
which is traditionally used to treat asthma, bronchitis and 
other complaints of the respiratory tract. This isolated 
component has proven anticoagulant action, but in general, 
no complaints are observed from users of guaco extract in 
relation to blood coagulation disorders. In a study in mice, 
extravasation of red blood cells of the pulmonary tissue 
was observed in animals treated with coumarin, which did 
not occur in the group treated with guaco extract (Santos 
et al., 2006)
The geographic location of the medicinal plants (as 
well as seasonality) can influence the production of marker 
substances of an extract. Extracts of Brazilian Orchid Tree 
(Bauhinia forficata) produced with leaves collected in the 
same period of the year, but from geographically different 
locations, presented different contents for their main ma-
rker, the flavonoid glycosilated campferitrin. Abundant 
in one extract and practically non-existent in another, 
this leads one to suppose that there is a difference in the 
pharmacological activity or in the quality of the extracts. 
However, quantifying the total flavonoids in both extracts, 
very similar total values are observed, which leads us to 
imagine that there is an internal compensation in the pro-
duction of the flavonoids by the plant, for environmental 
reasons, notwithstanding the expected pharmacological 
activity (Pinheiro et al., 2006).
The emerging microarray technology, which is a 
large-scale analysis technique, enables the simultaneous 
FIGURE 1 - Generic example of an iso-effect curve – 
isobologram, which demonstrates the presence of synergy or 
antagonism between two therapeutic agents. X and Y axes: ratio 
between the dose of combined agents 1 and 2 to the dose of 1 
and 2 in isolation, for the same biological effect. 
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evaluation of thousands of parameters in a single experi-
ment (for better understanding, see http://www.bio.davi-
dson.edu/Courses/genomics/chip/chip.html). It is particu-
larly effective for giving a general overview in the search 
for standards of gene expression in biological samples. 
Through the determination of the expression of thousand 
of genes simultaneously, the promising technology enables 
researchers to compare the molecular behavior of various 
types of cell strain and different tissues, when exposed to 
a determined pathological or experimental condition. The 
application of this technique in the study of plant extracts 
has proven the multi-target principle (Mischiati et al., 
2006; Ulrich-Merzenich et al., 2007), i.e. there is in fact a 
synergic interaction between the various components of 
an extract. For example, in a recent work which used this 
technique, the profiles of genetic responsiveness to the 
estrogen of two soy extracts were compared with the two 
corresponding isolated phytoestrogens. The gene expres-
sion obtained for the extracts was comparable to that of the 
isolated phytoestrogens, and 10 mM of daidzein isoflavone 
(3) correlated with the profile of the soy extracts, where 
the estimated daidzein concentration is around 100 times 
lower (Ise et al., 2005).
In this sense, one of the first published examples 
of synergy in phytotherapeutics was observed in Ginkgo 
biloba. Its pharmacological activity can be seen through 
TABLE I - Plant extracts with evidence of synergic/polyvalent activity
Species Majority constituents Effects Indications/uses
Hypericum
Hypericum perforatum
Hypericins, hyperforin, xanthones, 
flavonoids, procyanidins 
Inhibition of monoamine recapture; 
inhibition of MAO and COMT 
Procyanidin increases bioavailability 
of hypericin
Mild antidepressant
Kava-kava
Piper methysticum
Kavapyrones: Yangonin, demethoxy-
yangonin, dihydromethisticin
GABA
A 
facilitation; Inhibition of 
sodium and calcium canals; inhibition 
of NE recapture. Increase the 
bioavailability of the others
Ansiolytic, sedative, anticonvulsant, 
antispasmolytic, antiinflammatory
Valerian
V. officinalis
Valtrate, isovaltrate, valerenone, 
valerenic acid
Multiple GABA mechanisms Insomnia and sedative
Urtiga 
Urtica dioica (leaves)
Urtica dioica (root)
Oxylipin (13-hydroxyoctadecadienoic 
acic), derivatives of caffeic acid
Agglutinin (UDA)+ polyssacharides 
Inhibition of cyclooxygenase and 
cytosine
Immunostimulation
Arthritis and rheumatoid arthritis
Ginger
Zingiber officinale (essential oil)
a-Zingiberene, b-sesquifelandreno 
Bisabolene, curcumeno
Total extract with different effects 
from the isolated components.
Antipyretic, analgesic, sedative, 
antibiotic. 
Willow
Salix sp
Salicin and derivatives of salycilic 
alcohol, flavonoids, tanins.
Antiinflammatory and analgesic 
effects stronger than with isolated salicin 
Antiinflammatory and analgesic
Devil’s claw
Harpagophytum procumbens; 
H. zeyheri 
Harpagoside The components of the total extract 
cause stronger inhibition of the 
biosynthesis of the leukotriene 
and thromboxane than the isolated 
harpagoside 
Antiinflammatory and analgesic
Liquorice
Glycyrrhiza glabra 
Glycyrrhizin and isoliquiritin The extract increases the action of the 
hydrocortisone
Antiinflammatory and anti-cough 
Marijuana
Cannabis sativa 
Tetrahydrocanabinol (THC) e 
canabidiol (CBD)
THC has muscle relaxing, analgesics 
and appetite stimulating effects; CBD 
increases the antispasmodic activity 
Antispasmodic, aperient
Garlic
Allium sativum
Allicin and ajoene Inhibition of the expression of 
inducible nitric oxide expression in 
activated macrophages, inhibition 
of the platelet aggregation, ajoene 
induces apoptosis in leukemic cells, 
activates the production in intracellular 
peroxides 
Antiinflammatory, 
hypocholesterolemiant and 
hypotriglycerimiant, antioxidant, 
antimicrobial
Hawthorn
Crataegus oxyacantha
Procyanidins, flavonoids-C-
glycosylates
Inhibitor of the angiotensin converter 
enzyme; endothelin dependant relaxing 
effect of the smooth muscle
Cardiotonic
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in vitro tests of platelet aggregation. Ginkgolides (4) 
are known to be FAP antagonists, which is one of the 
mechanisms of antiinflammatory action. A mixture of 
ginkgolides A, B and C at a dose of 100-240 mg can 
generate a FAP-antagonist effect in humans, however, a 
dose of 120 mg of extract of standardized Ginkgo, which 
contains only 6-7 mg of ginkgolides, produces an equiva-
lent effect. As in the previous example, this means there 
are other substances that act at different levels, through 
other mechanisms, potentializing the effect of the isolated 
substance (Williamson, 2001).
Various works have been published on synergism 
and antimicrobial activity of plant extracts and their 
components, such as Berberis freemontii and its alkaloid 
berberine (5), whose activity is potentialized by the 
addition of two constituents of the plant, flavonolignan 
5’-methoxyhydrocarpine D (6) and porphryn pheophorbide 
a (7) in strains of Staphylococcus aureus. Although these 
substances potentialize the effects of a sub-therapeutic 
concentration of the alkaloid, none of them have antibiotic 
activity per se (Kinghorn, 2001).
Extracts of spices like oregano (Origanum vulgare) 
and mulberry (Vaccinium macrocarpon) present a com-
bined antimicrobial effect potentialized against Vibrio 
parahaemolyticus, an effect which is even more marked 
in the presence of lactic acid, suggesting that these may be 
viable alternatives for extending the preservation time of 
foods (Lin; Labbe; Shetty, 2005). The same extracts com-
bined were also active and synergic against Helicobacter 
pylori, and the author suggests managing this bacteria with 
a diet containing these juices (Vattem et al., 2005).
Another study which combines extracts of Salvia 
chamelaeagnea and Leonotis leonurus observed synergy 
when tested against Gram-positive bacteria (Bacillus ce-
reus and Staphylococcus aureus); however, antagonism 
was verified when the extracts were tested in Gram-negati-
ve bacterias (Escherichia coli and Klebsiella pneumoniae) 
(Kamatou et al., 2006).
A synergic effect has also been cited in the lite-
rature against extracts with high antioxidant potential 
(which exert capture of free radicals, due to the high 
quantity of polyphenolic substances) and antibiotics, 
and the authors suggest that the extracts may be used 
to increase the clinical effectiveness of antibiotics, or 
reduce their doses and prevent adverse effects. This was 
observed for the methanol extracts of Cordia gilletii and 
tetracycline in strains of Staphylococcus aureus which 
are resistant to methicillin (Okusa et al., 2007). The same 
effect was verified for 15 different plant extracts, inclu-
ding extract of Camellia sinensis (tea plant), Lawsonia 
inermis (henna), Mangifera indica (leaves of mango 
tree) and Punica granatum (pomegranate), which also 
demonstrate a synergic effect with tetracycline against 
Escherichia coli (ESbL-02) (Ahmad; Aqil, 2007). The 
flavone baicalin (8) is an important active constituent 
of the species Scutellaria baicalensis, used in Chinese 
medicine, which potentialized the effectiveness of both 
penicillin and ethanol extract of Notopterygium in strains 
of Staphylococcus aureus (Meng et al., 2006). Another 
researcher has the same opinion in relation to the isolated 
polyphenol epigallocatechin gallate and amphotericin B 
(Han, 2007). This synergic effect described by various 
authors demonstrates that the extracts are probably acting 
in different cell targets of the antibiotics.
Other studies have observed various forms of syner-
gy in cytotoxic and antitumoral activity of extracts, as in 
juice of pomegranate (Punica granatum), which presented 
antiproliferative activity in various strains of tumor cells, 
when compared with their isolated polyphenols (Seeram et 
al., 2005). Similarly, in another study, it was observed that 
the combination of four extracts significantly increased the 
antitumor activity, compared with the extracts in isolation 
(Adams et al., 2006).
Also, ethanol extract of the mushroom Phellinus 
igniarius presented synergic effect when combined with 
the chemotherapeutics Oxa (oxaliplatina) or 5-FU (5-Flu-
orouracil) (Song et al., 2008), and the natural flavolignan 
silibinin (9) showed synergy with the chemotherapeutics 
cisplatin and doxorubicin (Scambia et al., 1996).
A series of new studies has emerged in this area, 
and some traditional phytotherapeutics have now their 
mode of synergic action verified and their effectiveness 
scientifically proven – modern rational phytotherapy – 
exemplified in Table I.
An example of clinically investigated synergy to 
indicate the effectiveness of combinations of medicinal 
extracts is the association of valerian (Valeriana officina-
lis) with kava-kava (Piper methysticum), which proved 
to be better for the treatment of insomnia induced by 
stress than each of the extracts in isolation, like kava-
kava associated with passion fruit (Passiflora incarnata), 
which demonstrated a potentialized sedative hypnotic 
effect. Likewise, ginseng (Panax ginseng) associated 
with ginkgo (Ginkgo biloba) proved to be more effective 
in improving cognitive function than the isolated form, 
as measured by the performance in carrying out various 
arithmetic tasks (Williamson, 2001; Wagner, 2006).The 
central nervous system consists of an immense network 
of synaptic interactions, whose standard of functioning is 
eminently synergic. Hoasca is an indigenous term which 
defines an hallucinogenic fermented drink that has been 
used since ancient times, in the Orinoco and Amazonas 
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river basins for ceremonial and medicinal purposes, and 
has sacramental significance for indigenous peoples in 
the region (Peru, Bolivia, Ecuador, Brazil). This drink 
consists of a decoction of Banisteriopsis caapi (woody 
lian) and Psychotria viridis (leaves), and it is also known 
as ayahuasca, caapi, daime, yagé etc. The drink is con-
sumed every one or two weeks in a ceremonial context, 
and can present some tolerance, but does not cause physi-
cal or psychological dependence. Although other plants 
are included in the drink, scientific investigations have 
shown that the common denominator is the presence of 
the b-carboline alkaloids of the harmala type, particularly 
harmine (10), harmaline (11), tetrahydroharmine (THH) 
(12) and N,N-dimethylltryptamine (DMT) (13), which 
is considered responsible for the hallucinogenic effects. 
The amines THH and DMT increase the concentration 
of serotonin (5-HT) (14), the first through the inhibition 
of serotonin reuptake in the pre-synaptic sites and the 
second through the binding in serotonergic sites in the 
brain, facilitating new perceptions. However both are 
degraded by MAO-A (monoamino oxidase – type A) 
when administrated orally. This degradation does not 
occur in the case of the drink Hoasca, due to the presence 
of the alkaloids harmina and harmaline, which promote 
a synergic effect between the alkaloids, because they are 
specific and reversible inhibitors of MAO-A (IMAO-A), 
enabling the arrival of psychoactive agents (THH and 
DMT) in the brain (Figure 2) (Callaway et al., 1999).
To conclude, the study of synergy is an emerging 
field in all aspects, and there is much to be developed and 
understood in all areas of knowledge. New technological 
tools that enable the mechanisms of action of combined 
natural extracts or synthetic agents to be tracked will 
enable the creation and corroboration of differentiated 
medical therapies, increasing the quality of existing health 
treatments.
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